Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus (Q24246142)

2

J

Plank

1 reference

26 November 2023

A Berghold

3

A

Berghold

1 reference

26 November 2023

M Narath

4

M

Narath

1 reference

26 November 2023

R Gfrerer

5

R

Gfrerer

1 reference

26 November 2023

TR Pieber

6

T R

Cochrane Database of Systematic Reviews

Pieber

1 reference

26 November 2023

language of work or name

1 reference

18 October 2004

0 references

published in

0 references

cites work

Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Insulin lispro lowers postprandial glucose in prepubertal children with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Treatment with insulin lispro changes the insulin profile but does not affect the plasma concentrations of IGF-I and IGFBP-1 in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Effects of a fixed mixture of 25% insulin lispro and 75% NPL on plasma glucose during and after moderate physical exercise in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients. A comparison with human regular insulin during a three-meal test period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Metabolic and immunologic effects of insulin lispro in gestational diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: comparison with non-diabetic pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Insulin lispro is as effective as regular insulin in optimising metabolic control and preserving beta-cell function at onset of type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Human insulin analogue [LYS(B28), PRO(B29)]: the ideal pump insulin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Post-prandial insulin lispro vs. human regular insulin in prepubertal children with Type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Does insulin lispro preserve the physiological defences to hypoglycaemia during intensive insulin therapy with a conventional basal bolus regimen?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Use of insulin pump therapy at nighttime only for children 7-10 years of age with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Efficacy of Humalog injections before an afternoon meal and their acceptance by children and adolescents with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Insulin analogues and their potential in the management of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Validation of a diabetes-specific quality-of-life scale for patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Fear of hypoglycemia: quantification, validation, and utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Modeling absorption kinetics of subcutaneous injected soluble insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Risk factors of severe hypoglycaemia in adult patients with Type I diabetes--a prospective population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Reducing snacks when switching from conventional soluble to lispro insulin treatment: effects on glycaemic control and hypoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

The physiologic replacement of insulin. An elusive goal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Reliability and Validity of a Diabetes Quality-of-Life Measure for the Diabetes Control and Complications Trial (DCCT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

A Coefficient of Agreement for Nominal Scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

Time-action profile of the insulin analogue B28Asp

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Factors associated with nocturnal hypoglycaemia among patients with type 2 diabetes new to insulin therapy: experience with insulin lispro

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Impact of insulin lispro on HbA1c values in insulin pump users

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

The relationship between symptomatic and biochemical hypoglycaemia in insulin-dependent diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Do insulin-treated diabetic patients use an injection-meal-interval in daily life?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Counterregulatory hormone responses after long-term continuous subcutaneous insulin infusion with lispro insulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Postprandial insulin lispro. A new therapeutic option for type 1 diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021

Optimized basal-bolus therapy using a fixed mixture of 75% lispro and 25% NPL insulin in type 1 diabetes patients: no favorable effects on glycemic control, physiological responses to hypoglycemia, well-being, or treatment satisfaction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003287.PUB3

7 January 2021